All Posts Tagged With: "MDCO"
(BJ) Company News for June 10, 2011 – Corporate Summary
• On Thursday, 3M Company (NYSE:MMM) said it has concluded an agreement to buy manufacturer of quick cure, aircraft sealants Advanced Chemistry & Technology. The acquisition will enhance and expand 3M’s product availability in the aerospace market • ...
14Jun2011 | vitalstocks | 0 comments | Continued(BJ) Company News for June 10, 2011 – Corporate Summary
• On Thursday, 3M Company (NYSE:MMM) said it has concluded an agreement to buy manufacturer of quick cure, aircraft sealants Advanced Chemistry & Technology. The acquisition will enhance and expand 3M’s product availability in the aerospace market • ...
10Jun2011 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares
We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago...
27May2011 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Reports Fourth Quarter Earnings Beat
The Medicines Company (MDCO) reported a fourth-quarter profit of 27 cents per share, including the impact of stock-based compensation expense. Fourth quarter profit exceeded the Zacks Consensus Estimate of 24 cents and the year-ago loss of 57 cents. Performance was boosted by...
22Feb2011 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Receives Good Patent News
We recently reiterated our Outperform recommendation on The Medicines Company (MDCO). In August 2010, The Medicines Company received good news with the US District Court for the Eastern District of Virginia ordering the US Patent and Trademark Office (PTO) to treat The Medicines...
10Dec2010 | vitalstocks | 1 comment | Continued(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
15Nov2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Earnings Well Above on Lower Costs
The Medicines Company (MDCO) reported a third-quarter profit of 40 cents per share Incorporatedluding the impact of stock-based compensation expense. Third quarter profit was well above the Zacks Consensus Estimate of 24 cents and the year-ago loss of 6 cents. Performance was...
3Nov2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Shares Uppgraded to Outperform
We recently upgraded The Medicines Company (MDCO) to Outperform based on our improved outlook on the stock. In August 2010, The Medicines Company received good news when the US District Court for the Eastern District of Virginia ordered the US Patent and Trademark Office (PTO)...
12Oct2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company – Bull of the Day
The Medicines Co. (MDCO) reported second-quarter EPS of $0.29, well above the Zacks Consensus Estimate and the year-ago EPS. Performance was boosted by higher revenues and lower operating expenses. Revenues increased 5.7%. The company received a major boost in August regarding...
11Oct2010 | vitalstocks | 0 comments | Continued(MDCO) Medicines Company Tops Street Estimates
The Medicines Co. (MDCO) reported a second-quarter profit of 27 cents per share Incorporatedluding the impact of stock-based compensation expense. Second quarter profit was well above the Zacks Consensus Estimate of 23 cents and the year-ago earnings of 8 cents. Performance was...
29Jul2010 | vitalstocks | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
26Jul2010 | vitalstocks | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
20Jul2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Gives Angiomax Update
The Medicines Company (MDCO) recently announced that the US District Court for the Eastern District of Virginia has ordered the US Patent and Trademark Office (PTO) to take necessary actions so as to make sure that the company’s patent on Angiomax does not expire until 10 days...
24May2010 | vitalstocks | 0 comments | Continued(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Apr2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Co. Challenges U.S. Patent and Trademark Office Decision
In a continued attempt to get its Angiomax patent extended, The Medicines Co. (MDCO) recently filed yet another lawsuit against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services. This time,...
29Mar2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company’s Patent Extension Denied
A couple of days after The Medicines Co. (MDCO) received a breather in the form of a favorable court order in its lawsuit against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services, the...
25Mar2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company’s Patent Extension is Denied
A couple of days after The Medicines Company (MDCO) received a breather in the form of a favorable court order in its lawsuit against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services,...
23Mar2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Wins Favorable Court Order
The Medicines Company (MDCO) received a much needed breather recently in the form of a favorable order issued by the U.S. District Court for the Eastern District of Virginia in the company’s lawsuit against the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug...
18Mar2010 | vitalstocks | 0 comments | Continued(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Jan2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company is Upgraded to Neutral
We recently upgraded our recommendation on The Medicines Company (MDCO) to Neutral from Underperform. Despite the economic slowdown and cost-cutting by hospitals, The Medicines Company’s lead product Angiomax continues to perform well. We expect Angiomax sales to remain strong...
4Jan2010 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Co Recalls Cleviprex Lots
The Medicines Co. (MDCO) recently announced the voluntary recall of eleven lots of Cleviprex (clevidipine butyrate) injectable emulsion. During a routine annual inspection, the presence of visible particulate matter was observed in some vials. However, The Medicines Co. stated...
18Dec2009 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Gets Angiox Label Expanded
The Medicines Company (MDCO) recently received positive news in the form of a label expansion for Angiox in the EU. The European Commission granted approval for the use of Angiox as an anticoagulant in patients with heart attacks [ST-segment elevation myocardial infarction (STEMI)]...
3Dec2009 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company – Bear of the Day
The Medicines Company‘s (MDCO) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Although Angiomax continues to contribute significantly to revenues, we are concerned about the product losing exclusivity in the U.S. in September...
29Nov2009 | vitalstocks | 0 comments | Continued(MDCO) Medicines Company – Bear of the Day
The Medicines Company’s (MDCO) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Although Angiomax continues to contribute significantly to revenues, we are concerned about the product losing exclusivity in the U.S. in September...
19Nov2009 | vitalstocks | 0 comments | Continued(MDCO) Medicines Co. Misses Forecasts & Cuts Projections
Medicines Co.’s (MDCO) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Revenues increased 12% to $98.8 million from $88.13 million in the year ago period driven by strong sales of Angiomax (bivalirudin). Angiomax, the lead product...
2Nov2009 | vitalstocks | 0 comments | Continued(MDCO) Medicines Company’s Angiomax Anti-Clotting Drug Promising
Medicines Co. (MDCO) yesterday presented encouraging results from its landmark HORIZONS-AMI study on anti-clotting drug, Angiomax. The company stated that treatment with Angiomax resulted in improved survival rates in patients who had suffered from the most severe form of heart...
2Sep2009 | vitalstocks | 0 comments | Continued